Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of 5 X 10^7 PFU RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated With High Risk HPV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Tipapkinogene sovacivec (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- Sponsors Roche
- 05 Jun 2019 According to a Transgene media release, results from the study have been published in the Gynecologic Oncology.
- 05 Jun 2019 Primary endpoint has been met. (Percentage of participants with CIN2/CIN3 associated with HPV16 single infection who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision), according to a Transgene media release.
- 05 Jun 2019 Results presented in a Transgene media release.